Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03718130 · ClinicalTrials.gov registry record · Phase 1
Combination HTNV and PUUV DNA Vaccine
A Phase 1 study of Hantaan Virus Disease, Puumala Virus, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT03718130 is a Phase 1 study of Hantaan Virus Disease, Puumala Virus that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 61 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03718130, a Phase 1 study of Hantaan Virus Disease, Puumala Virus, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
Conditions Studied
Interventions
- COMBINATION_PRODUCT Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
- COMBINATION_PRODUCT Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
- COMBINATION_PRODUCT Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
- COMBINATION_PRODUCT Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
- COMBINATION_PRODUCT Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Study Locations (1)
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03718130
The ClinicalTrials.gov registry entry for NCT03718130 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hantaan Virus Disease, Puumala Virus appearing as the primary indexed condition, and to 5 interventions - of which Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID) is the first listed.
NCT03718130 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03718130 about?
NCT03718130 is a clinical study titled "Combination HTNV and PUUV DNA Vaccine". To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
What is the current status of trial NCT03718130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-07-10. Estimated completion is 2022-10-07.
What conditions does trial NCT03718130 study?
This clinical trial studies the following conditions: Hantaan Virus Disease, Puumala Virus.
What interventions are being tested in trial NCT03718130?
The interventions under investigation include: Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID) (COMBINATION_PRODUCT), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM) (COMBINATION_PRODUCT), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID) (COMBINATION_PRODUCT), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM) (COMBINATION_PRODUCT), Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03718130?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03718130 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.